About Us
WhiteLab Genomics stands at the convergence of AI and biology. Founded in 2019, backed by Y-Combinator, we are pioneering the accelerated development of life-saving genomic medicines. By leveraging our proprietary technology, WhiteLab Genomics uses AI and advanced computational methods to analyze complex biological data to significantly accelerate and de-risk drug development.
Our Mission
Unleash the Potential of Genomic Medicine Using AI
We improve therapeutic target discovery and delivery by predicting the optimal molecular design for specific target product profiles to expedite and de-risk the development of genomic medicines.
Our Value Proposition
- Our in silico approach, bolstered by external wet lab capabilities and proprietary data, allows us to deliver industry-leading modules with unmatched agility and scalability across therapeutic areas
- Our multi-disciplinary platform teams develop tailored solutions to de-risk R&D advancements to achieve target product profiles
- We use a guided rational approach to identify the most effective target-ligand combinations, addressing challenges across delivery methods and tissue targets
Our Team
Strategic Minds, Transformative Impact
Headquartered in Paris and Boston, our diverse team of innovators combines deep industry expertise with bold scientific vision across a wide range of disciplines.
Discover WhiteLab Genomics01:57
Our Partners
